Evidence map›Paper›PMID 21272100›Full record

ArticleThe European journal of neuroscience2011

Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Kavita Prasad, Elizabeth Tarasewicz, Pamela A Ohman Strickland, Michael O'Neill, Stephen N Mitchell, Kalpana Merchant, Samnang Tep, Kathryn Hilton, Akash Datwani, Manuel Buttini and 2 more

Abstract read
In one paragraph

Article in The European journal of neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease.International journal of molecular sciences · 2020
    Review
  4. Historical Perspective: Models of Parkinson's Disease.International journal of molecular sciences · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
  10. Parkinson's disease mouse models in translational research.Mammalian genome : official journal of the International Mammalian Genome Society · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Kavita PrasadDepartment of Pathology and Lab Medicine, Robert Wood Johnson Medical School (RWJMS), Piscataway, NJ 08854, USA.
Elizabeth Tarasewicz
Pamela A Ohman Strickland
Michael O'Neill
Stephen N Mitchell
Kalpana Merchant
Samnang Tep
Kathryn Hilton
Akash Datwani
Manuel Buttini
Sarah Mueller-Steiner
Eric K Richfield
Eli Lilly (United Kingdom) · GBEnvironmental and Occupational Health Sciences Institute · USEli Lilly (United States) · USJohnson University · USRutgers, The State University of New Jersey · US

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
NIEHS NIH HHS P30 ES005022NIEHS NIH HHS P30ES005022
6 · The paper itself

Abstract

A consensus about the functions of human wild-type or mutated α-synuclein (αSYN) is lacking. Both forms of αSYN are implicated in Parkinson's disease, whereas the wild-type form is implicated in substance abuse. Interactions with other cellular proteins and organelles may meditate its functions. We developed a series of congenic mouse lines containing various allele doses or combinations of the human wild-type αSYN (hwαSYN) or a doubly mutated (A30P*A53T) αSYN (hm(2) αSYN) in a C57Bl/6J line spontaneously deleted in mouse αSYN (C57BL/6JOla). Both transgenes had a functional role in the nigrostriatal system, demonstrated by significant elevations in striatal catecholamines, metabolites and the enzyme tyrosine hydroxylase compared with null-mice without a transgene. Consequences occurred when the transgenes were expressed at a fraction of the endogenous level. Hemizygous congenic mice did not exhibit any change in the number or size of dopaminergic neurons in the ventral midbrain at 9 months of age. Human αSYN was predominantly located in neuronal cell bodies, neurites, synapses, and in intraneuronal/intraneuritic aggregates. The hm(2) αSYN transgene resulted in more aggregates and dystrophic neurites than did the hw5 transgene. The hwαSYN transgene resulted in higher expression of two striatal proteins, synaptogamin 7 and UCHL1, compared with the levels of the hm(2) αSYN transgene. These observations suggest that mutations in αSYN may impair specific functional domains, leaving others intact. These lines may be useful for exploring interactions between hαSYN and environmental or genetic risk factors in dopamine-related disorders using a mouse model.

Indexed as

Mice, KnockoutMice, Transgenicalpha-SynucleinAnimalsCatecholaminesChromatography, High Pressure LiquidCorpus StriatumHippocampusHumansMiceMice, Inbred C57BLNeurodegenerative DiseasesNeuronsSubstance-Related DisordersSynapsesTransgenesalpha-SynucleinCatecholamines

Identifiers

PMID21272100
PMCPMC3072281
OpenAlexW1583625687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.